Bayer Advancing Cell, Gene Therapies for Parkinson's Disease
08 Junio 2021 - 7:00AM
Noticias Dow Jones
By Colin Kellaher
Bayer AG on Tuesday said it is advancing a pair of therapies
targeting the neurodegenerative movement disorder Parkinson's
disease.
The German company said its BlueRock Therapeutics unit has
administered the first dose of its investigational pluripotent stem
cell-derived dopaminergic neurons, named DA01, to a Parkinson's
disease patient in an open-label Phase 1 clinical safety and
tolerability study.
In a parallel gene-therapy program, Bayer's Asklepios
BioPharmaceutical Inc. unit is recruiting and evaluating patients
in a Phase 1b study to assess safety and preliminary efficacy.
Bayer said there is currently no disease-modifying treatment
available for Parkinson's disease, which affects more than 10
million people around the world.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 08, 2021 07:51 ET (11:51 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Bayer (TG:BAYN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
